Last updated: 2026-09-09 04:54:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
C4 Therapeutics, Inc. (CCCC) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $3.56, with a market capitalization of $462.57M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.69 to $5.17. This page covers its latest market performance, valuation, price trends and company information.
$462.57M | |
$3.72 | |
$51.21 | |
$1.06 | |
$3.76 | |
2.05M | |
2.99M | |
-- | |
$5.17 | |
$1.69 | |
-- | |
-- |
C4 Therapeutics, Inc. (CCCC) last closed at $3.76 as of 2026-09-09 00:00:00, unchanged from the previous close of $3.76.
During the latest regular trading session, CCCC traded between $1.06 and $51.21, with a volume of 2.05M shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, C4 Therapeutics, Inc. (CCCC) moved from $4.10 to $3.56, representing a decline of 13.29% ($0.54).
The stock traded between $3.56 and $4.30 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.07 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 53.6%
CCCC is currently trading at $3.56, placing it 53.6% of the way from its 52-week low of $1.69 to its 52-week high of $5.17. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 104 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of C4 Therapeutics, Inc. (CCCC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.